<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186979">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659633</url>
  </required_header>
  <id_info>
    <org_study_id>F061204014</org_study_id>
    <nct_id>NCT00659633</nct_id>
  </id_info>
  <brief_title>The Effect of Intravenous Lidocaine on Allodynia</brief_title>
  <official_title>The Effect of Intravenous Lidocaine on Allodynia (Carl Koller Grant)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Regional Anesthesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study if lidocaine, given intravenously, reduces pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinicians use lidocaine intravenously in a fashion that suggests that it might have
      analgesic effects. Therefore, we test the hypothesis that lidocaine reduces pain intensity
      in response to experimental pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropathic Pain</measure>
    <time_frame>Participants will be followed for the duration of test, an expected average of 128 minutes</time_frame>
    <description>Assessing neuropathic pain intensity before, during, and after saline or lidocaine infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory Function</measure>
    <time_frame>Participants will be followed for the duration of test, an expected average of 128 minutes</time_frame>
    <description>Assessing sensory function (pain intensity) before, during, and after saline or lidocaine infusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Perception</measure>
    <time_frame>Participants will be followed for the duration of test, an expected average of 128 minutes</time_frame>
    <description>Assessing pain perception (pain intensity) before, during, and after saline or lidocaine infusion</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous lidocaine for neuropathic pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <other_name>Lidoderm</other_name>
    <other_name>Xylocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Regional Pain Syndrome diagnostic criteria by the Work Safe BC. vi

        Exclusion Criteria:

          -  History of Substance abuse

          -  Other Medications: CRPS patients are expected to be treated for chronic pain, whether
             the current treatment regimen interferes with sensory motor testing will be
             determined on a case by case basis.

          -  Coronary Artery Disease (CAD): unstable

          -  Congestive Heart Failure (CHF): unstable

          -  Heart Arrhythmia: symptomatic

          -  Chronic Obstructive Pulmonary Disease (COPD)

          -  Lidocaine Allergy

          -  Diagnostic and Statistical Manual of Mental Disorders (Rev IV): Axis I: Common Axis I
             disorders include depression, anxiety disorders, bipolar disorder, ADHD, and
             schizophrenia. Axis II: borderline personality disorder, schizotypal personality
             disorder, antisocial personality disorder, and mild mental retardation.

          -  Presence of Contraindications for MRI

          -  Presence of electronically, magnetically, and mechanically activated implants

          -  Electronically, magnetically, and mechanically activated implants

          -  Ferromagnetic or electronically operated active devices like automatic cardioverter
             defibrillators

          -  Cardiac pacemakers

          -  Metallic splinters in the eye

          -  Ferromagnetic haemostatic clips in the central nervous system (CNS)

          -  Claustrophobia

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Froelich, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 14, 2016</lastchanged_date>
  <firstreceived_date>April 14, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michael Froelich</investigator_full_name>
    <investigator_title>Associate Proffesor Anesthesiology M.D.</investigator_title>
  </responsible_party>
  <keyword>lidocaine</keyword>
  <keyword>allodynia</keyword>
  <keyword>chronic regional pain syndrome</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
